AN2 Therapeutics, Inc. Stock Price, News & Analysis

AN2 Therapeutics (Nasdaq: ANTX) announced a collaboration with GSK to develop boron-based LeuRS inhibitors targeting tuberculosis, announced November 10, 2025.

The Gates Foundation will provide a third year of funding to support AN2’s role in the collaboration. AN2 highlighted its boron chemistry platform and cited LeuRS as a validated target underlying epetraborole, ganfeborole and the FDA-approved tavaborole.

AN2 and GSK said the partnership aims to advance novel small-molecule TB therapies, with AN2 contributing boron-chemistry expertise and GSK contributing Global Health R&D resources.

AN2 Therapeutics (Nasdaq: ANTX) announced that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held December 2-4, 2025.

The fireside chat is scheduled for Wednesday, December 3, 2025 at 10:50 AM ET. Management will be available for 1x1 meetings. A live webcast will be accessible from the company's Investor Relations website and an archived replay will be available for at least 30 days after the presentation.

AN2 Therapeutics (Nasdaq: ANTX) reported Q2 2025 financial results and pipeline updates across multiple programs. The company ended Q2 with $71.2 million in cash, projecting runway into 2028. Key highlights include: initiation of Phase 1 trials for AN2-502998 in Chagas disease, collaboration with DNDi, and promising data from a 200-patient melioidosis study showing 40% mortality rate highlighting urgent treatment needs.

The company is advancing two oncology programs with expected development candidates within 12 months: a 3rd generation PI3Kα inhibitor and an ENPP1 inhibitor. Q2 financial results showed reduced R&D expenses of $3.2 million (vs $12.1M in Q2 2024) and a net loss of $6.5 million (vs $14.4M in Q2 2024).

AN2 Therapeutics (Nasdaq: ANTX) has reached a significant milestone in its clinical development program by completing the first single ascending dose cohort in its Phase 1 first-in-human trial of oral AN2-502998 for Chagas disease. The drug candidate shows potential as a curative treatment for chronic Chagas disease, which affects 6-7 million people globally.

The company expects to complete Phase 1 dosing by end of 2025, with Phase 2 proof-of-concept data anticipated within their cash runway. Preclinical studies in nonhuman primates have demonstrated promising curative potential. Through collaboration with Drugs for Neglected Diseases initiative (DNDi), Phase 2 trials are planned to begin in 2026 with data expected in 2027.

AN2 Therapeutics (Nasdaq: ANTX) has announced a strategic collaboration with Drugs for Neglected Diseases initiative (DNDi) to advance the clinical development of AN2-502998, an oral drug candidate for chronic Chagas disease treatment. The partnership leverages DNDi's extensive clinical trial network and expertise in Latin America and Spain.

The collaboration aims to accelerate the development of AN2-502998, with Phase 1 first-in-human studies currently starting and Phase 2 studies planned for 2026. Chagas disease, affecting 6-7 million people globally including 300,000 in the U.S., is caused by the Trypanosoma cruzi parasite and can lead to serious heart and gastrointestinal complications in approximately 30% of chronic cases.

AN2 Therapeutics (Nasdaq: ANTX) has completed a significant 200-patient observational study in acute melioidosis, funded by the National Institutes of Health. The study revealed a striking 40% mortality rate by Day 90 among confirmed melioidosis cases, with an additional 25% of screened patients dying before definitive diagnosis.

The study was conducted across three sites in melioidosis-endemic regions, evaluating patients receiving the current standard of care (IV meropenem or ceftazidime). The research was completed in just 11 months and tracked patients for over 90 days, providing critical data for the company's upcoming Phase 2 proof-of-concept trial of epetraborole.

The company plans to submit an IND and initiate its Phase 2 trial later this year. If approved for acute melioidosis treatment, AN2 Therapeutics would seek a priority review voucher and could generate revenue from government stockpiling and treatment use in endemic countries, including the U.S., as B. pseudomallei is classified as a high-priority biothreat agent.

AN2 Therapeutics (NASDAQ: ANTX) announced a poster presentation at the 2025 Colorado Mycobacteria Conference showcasing preclinical data of epetraborole against M. abscessus. The presentation, scheduled for May 29, 2025, will highlight the drug's potential as an oral treatment for M. abscessus lung disease, which affects approximately 50,000 patients in the U.S., Japan, and Europe, with an estimated all-cause mortality rate of 45%. The poster, titled "Epetraborole, a Potential Oral Agent for Mycobacterium abscessus Lung Disease," will be presented by Dr. MRK Alley and will be simultaneously available on AN2 Therapeutics' website.

AN2 Therapeutics (ANTX) reported Q1 2025 financial results and pipeline updates. The company ended Q1 with $78.5 million in cash and investments, extending runway into 2028. Key highlights include:

Pipeline developments:

• Initiated Phase 1 study for AN2-502998 in Chagas disease, with potential $1 billion peak sales
• Planning Phase 2 study of epetraborole for melioidosis
• Advancing epetraborole for M. abscessus NTM lung disease
• Developing oncology programs targeting ENPP1 and PI3Kα

Financial results show reduced losses with net loss of $10.6 million vs $16.6 million in Q1 2024. R&D expenses decreased to $7.7 million from $14.7 million, while G&A expenses slightly increased to $3.8 million from $3.6 million.

AN2 Therapeutics (NASDAQ: ANTX) reported that its Phase 3 EBO-301 study for epetraborole in MAC lung disease failed to meet its primary endpoint. Despite this setback, the company is pivoting focus to its broader boron chemistry pipeline. Key developments include: Pipeline Updates: - Initiated Phase 1 study of AN2-502998 for Chagas disease, with estimated $1B peak sales potential - Planning Phase 2 study for epetraborole in melioidosis in 2H25 - Pursuing M. abscessus lung disease treatment through non-dilutive funding - First oncology compounds targeting ENPP1 and PI3Kα expected to enter development in 2H25 Financial Position: - $78.5M cash position as of March 31, 2025 - Extended cash runway into 2028 - Implemented strategic workforce reduction and operational optimization